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Transgenic mice overexpressing growth hormone (GH) spontaneously develop 
liver tumors, including hepatocellular carcinoma (HCC), within a year. The 
preneoplastic liver pathology in these mice recapitulates that observed in 
humans at high risk of developing hepatic cancer. Although increased 
expression of galectin 1 (GAL1) in liver tissue is associated with HCC 
aggressiveness, a link between this glycan-binding protein and hormone-related 
tumor development has not yet been explored. In this study we investigated 
GAL1 expression during liver tumor progression in mice continuously exposed 
to high levels of GH. GAL1 expression was determined by Western blotting, RT-
qPCR and immunohistochemistry in the liver of transgenic mice overexpressing 
GH. Animals of representative ages at different stages of liver pathology were 
studied. GAL1 expression was up-regulated in the liver of GH-transgenic mice. 
This effect was observed at early ages, when animals displayed no signs of 
liver disease or minimal histopathological alterations and was also detected in 
young adults with preneoplastic liver pathology. Remarkably, GAL1 up-
regulation was sustained during aging and its expression was particularly 
enhanced in liver tumors. GH also induced hepatic GAL1 expression in mice 
that were treated with this hormone for a short period. Moreover, GH triggered a 
rapid increment in GAL1 protein expression in human HCC cells, denoting a 
direct effect of the hormone on hepatocytes. Therefore, our results indicate that 
GH up-regulates GAL1 expression in mouse liver, which may have critical 
implications in tumorigenesis. These findings suggest that this lectin could be 
implicated in hormone-driven liver carcinogenesis.
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Liver cancer is the third most common cause of cancer-related deaths 
worldwide (1). Hepatocellular carcinoma (HCC) accounts for 90% of liver 
tumors and it is strongly associated with chronic Hepatitis B or C virus infection, 
alcohol abuse or nonalcoholic steatohepatitis. Regardless of the carcinogenic 
insult, it usually develops in patients with cirrhosis due to chronic inflammation 
and advanced fibrosis (2).
Growth hormone (GH) is a major regulator of body growth and 
metabolism. This hormone is secreted by the pituitary gland and acts directly on 
target cells by signaling through its membrane-associated receptor. GH also 
promotes insulin-like growth factor type 1 (IGF1) synthesis, principally in the 
liver, which then serves as an endocrine factor mediating GH actions in other 
tissues (3, 4, 5).
Evidence from both humans and animal models revealed a link between 
GH/IGF1 status and cancer risk (5, 6, 7, 8, 9). In particular, aberrations in the 
somatotropic axis have been implicated in the development of liver tumors in 
rodents. While GH-deficient mice are resistant to the development of 
carcinogen-induced liver tumors (10), transgenic mice overexpressing GH 
spontaneously develop hepatocellular tumors, including HCC, within a year (11, 
12, 13, 14). Remarkably, liver pathology preceding the development of HCC is 
characterized by a sustained increase in hepatocyte turnover and development 
of chronic inflammation (11, 12, 15). Therefore, mice overexpressing GH 
constitute an appropriate model for the study of liver tumorigenesis as 
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preneoplastic liver pathology observed in these animals recapitulates that 
present in patients at high risk of developing hepatic cancer (12, 16, 17).
Galectin 1 (GAL1), a proto-type member of the galectin family with 
affinity for β-galactoside-enriched glycoconjugates, plays key roles during liver 
tumorigenesis (18, 19, 20). Particularly in human HCC, GAL1 overexpression 
correlates with tumor cell migration and invasion, metastasis and shortened 
patient survival (20, 21, 22). Patients with advanced HCC had significantly 
higher serum levels of GAL1 compared to healthy volunteers (23). Furthermore, 
we have demonstrated that GAL1-overexpressing HCC cells display higher 
tumorigenic and metastatic potential when inoculated into immunodeficient mice 
(24). 
Although increasing levels of GAL1 are often a hallmark of HCC 
aggressiveness (18, 19, 20, 21, 23, 24, 25), there is still no information on how 
endogenous stimuli control its expression in vivo and whether it plays a role in 
hormone-driven carcinogenesis. In this work we show that prolonged 
unremitting exposure to GH induces GAL1 expression in mouse liver, which 
may have critical implications in tumorigenesis. 
Materials and methods
Growth hormone (GH)-transgenic mice
Transgenic PEPCK-bGH mice containing the bovine GH gene fused to control 
sequences of the rat phosphoenolpyruvate carboxykinase (Pepck) gene have 
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been previously described (17, 26). Hemizygous transgenic mice were 
produced by mating transgenic males with normal C57BL/6 X C3H F1 hybrid 
females purchased from the Jackson Laboratory (Bar Harbor, ME). These mice 
had markedly accelerated postweaning growth, leading to a significant increase 
in body weight and organomegaly. Normal-sized siblings of transgenic mice 
were used as controls. Mice were housed five per cage in a room with 
controlled light (12h light per day) and temperature (22±2°C) and had free 
access to food (Rodent Laboratory Chow 5001; not autoclaved; 23.4% w/w 
protein, 4.5% w/w fat, 5.8% w/w crude fiber; LabDiet, PMI Feeds, Inc., St. Louis, 
MO, USA) and water.
Animals were fasted for 5h and then killed by cervical dislocation under 
isofluorane anesthesia. Livers, skeletal muscles from the hind limb, hearts and 
kidneys were removed and stored at -70°C until use. In old GH-transgenic mice 
(10-13 months-old), liver tumor and non-tumor areas were removed, processed 
in parallel and stored as described above. For histopathological analysis, a 
piece of liver from each animal was fixed and paraffinized following standard 
procedures. 
Experiments were conducted in accordance with the NIH Guidelines for 
the Care and Use of Experimental Animals. Animal protocols were approved by 
the Southern Illinois University Laboratory Animal Care and Use Committee.
GH administration to Swiss-Webster mice
Adult (3-4 months-old) Swiss-Webster female and male mice were used. 
Animals were housed 3-5 per cage in a room with controlled light (12h light: 12h 
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darkness cycle) and temperature (22±2°C). Mice had free access to a 
nutritionally balanced diet and tap water. 
Highly purified porcine GH (Zamira Life Sciences Pty Ldt, Knoxfield, VIC, 
Australia) was subcutaneously administered to Swiss-Webster mice for 5 days 
under continuous infusion with an osmotic minipump (model 1007D, Alzet) 
delivering the hormone at a dose 1mg/kg of body weight per day, as previously 
described (27). Control animals were treated in a similar fashion but saline 
solution was administered instead. Five days after minipump implantation, 
animals were fasted for 6h and then killed by cervical dislocation. Livers were 
removed and stored frozen at -70°C until homogenization and preparation of 
liver extracts for immunoblotting (27). 
The appropriateness of the experimental procedure, the required number 
of animals and the method of acquisition were in compliance with federal and 
local laws and with institutional regulations. Animal protocols were approved by 
the Laboratory Animal Care Committee of the School of Pharmacy and 
Biochemistry of the University of Buenos Aires.
Cell culture
The human HCC cell lines HepG2/C3A (ATCC CRL-10741, a clonal derivative 
of HepG2 cell line ATCC HB-8065) and HuH-7 (ICRB 0403) were cultured in 
Dulbecco’s modified Eagle medium (DMEM, Gibco, Life Technologies-
Invitrogen Corporation, Carlsbad, CA) containing 4.5g/l glucose, supplemented 
with 10% v/v fetal bovine serum (Natocor, Córdoba, Argentina), 0.002mol/L L-
glutamine and antibiotics in a humidified atmosphere of 5% CO2 at 37ºC. 
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Experiments were performed with low-passage cell cultures (<20 passages). 
Cells were cultured in serum-free media for 24h and then treated with 0.5 or 
1μg/ml human recombinant GH (European Pharmacopoeia) in the absence of 
serum for the indicated times. After treatment, cells were processed for 
quantitative RT-PCR analysis and immunoblotting.
Quantitative RT-PCR (RT-qPCR) analysis
Total RNA was extracted from liver tissue and cells using TRIzol Reagent 
(InvitrogenTM, Thermo Fisher Scientific, Carlsbad, CA, USA) following the 
manufacturer's instructions. cDNA was obtained using iScript cDNA synthesis 
kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA). For RT-qPCR, primer sets 
were designed for the specific amplification of galectin 1 (GAL1; encoded by the 
Lgals1 gene) and Cyclophilin A or RPL13A as reference genes. Sense and 
antisense oligonucleotide primers were designed following general 
recommendations with the public software Primer BLAST and OligoPerfectTM 
Designer (Thermo Fisher Scientific, Inc., Waltham, MA, USA) and were 
obtained from Invitrogen. The sequence of primers (5’→3’) are: Gal1 F: 
TGAACCTGGGAAAAGACAGC, Gal1 R: TCAGCCTGGTCAAAGGTGAT, GAL1 
F: GGAACATCCTCCTGGACTCA, GAL1 R: ACGAAGCTCTTAGCGTCAGG, 
Cyclophilin A F: GCGTCTCCTTGAGCTGTT, Cyclophilin A: R: 
TCAGCCTGGTCAAAGGTGAT, RPL13A F: TGACAAGAAAAAGCGGATGGTG 
RPL13A R: GCTGTCACTGCCTGGTACTT. Each sample was assayed in 
duplicate using 4pmol of each primer, 1× SYBR® Select Master Mix (Applied 
BiosystemsTM, Thermo Fisher Scientific, Carlsbad, CA, USA) and 25ng of 
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reverse-transcribed RNA in a total volume of 13μl. Amplification was carried out 
in a Step One PlusTM Real-Time PCR System (Applied BiosystemsTM). 
Dissociation curves were generated at the end of each run in order to detect 
non-specific products and validate the results. Relative gene expression levels 
were calculated according to the comparative cycle threshold (Ct) method which 
refers results from each experimental sample to a calibrator, in this case the 
average Ct value of the corresponding run, and calculates the relative change 
as 2−ΔCt. Target gene relative expression levels were normalized by Cyclophilin 
A expression levels. To validate this method of relative quantification, the 
amplification efficiencies of target and reference genes were measured and 
shown to be approximately equal and close to 100%.
Immunoblotting
Tissues and cells were homogenized in solubilization buffer (0.1mol/L Hepes, 
pH 7.4, 1% v/v Triton X-100, 0.1mol/L sodium pyrophosphate, 0.1mol/L sodium 
fluoride, 0.01mol/L EDTA, 0.01mol/L sodium vanadate, 0.002mol/L 
phenylmethylsulfonyl fluoride (PMSF) and 0.035units/mL aprotinin). 
Homogenates were centrifuged at 100,000g at 4°C for 60min to remove 
insoluble material. Protein concentration of supernatants was determined by the 
bicinchoninic acid (BCA) assay (Pierce™ BCA Protein Assay Kit, Thermo 
Fisher Scientific). Forty μg total protein of each solubilized sample were 
resolved by 12% SDS-polyacrylamide gel electrophoresis. For immunoblotting, 
proteins were transferred to polyvinylidene fluoride (PVDF) membranes 
(Amersham Hybond P 0.45 PVDF blotting membrane, GE Healthcare Life 
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Sciences, Chicago, IL, USA) and probed with goat anti-GAL1 polyclonal 
antibody 1:1000 (sc-19277, Santa Cruz Biotechnology, Dallas, TX, USA) 
overnight at 4ºC, followed by a 60min-incubation with horseradish peroxidase 
(HRP)-conjugated secondary antibody (sc-2020, Santa Cruz Biotechnology). 
Primary antibody specificity has been demonstrated in GAL1-knocked-down 
cells previously (28, 29). Immunoreactive bands were detected by 
chemiluminiscence (Pierce™ ECL Plus Western Blotting Substrate, Thermo 
Fisher Scientific). Protein loading control could not be assessed by 
immunoblotting of standard proteins in the liver for GH-overexpressing mice 
since actin exhibits age and genotype-dependent variation in hepatic protein 
abundance, whereas tubulin does not react uniformly between genotypes (17, 
30). Therefore, protein loading control was performed by relativizing protein 
content to Coomassie blue staining of PVDF membranes after blotting 
experiments as previously described (17, 30, 31). Of note, in experiments using 
cell lines and Swiss-Webster mice, protein loading control was performed by β-
actin immunoblotting (rabbit anti-β-actin polyclonal antibody, 1:1000, A2066 
Sigma-Aldrich Co, St. Louis, MO). Protein quantification was performed by 
densitometric analysis using ImageJ software (National Institutes of Health, 
Bethesda, MD, USA). 
Immunohistochemistry
Freshly dissected livers were fixed overnight in 4% w/v paraformaldehyde and 
embedded in paraffin. Liver sections (5μm thickness) were transferred onto 
glass slides, deparaffinized and rehydrated. After antigenic recuperation with 
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sodium citrate (pH 6.0) at 98°C for 30min, non-specific proteins were blocked 
using 1% w/v BSA in PBS for 1h followed by normal horse serum for 2h. Liver 
sections were incubated overnight at 4°C with anti-GAL1 antibody (1:200, sc-
19277, Santa Cruz Biotechnology). Afterwards, incubation with biotin-labeled 
secondary antibody followed by incubation with streptavidin-horseradish 
peroxidase complex (R.T.U. Vectastain kit, Vector Laboratories, Burlingame, 
CA, USA) were each performed for 30min at room temperature. Endogenous 
peroxidase activity was blocked incubating slides on PBS containing 3% v/v 
hydrogen peroxide for 30min. Tissues were incubated with 1% w/v BSA in PBS 
instead of the primary antibody as negative control. Antigen-antibody binding 
was visualized with the DAB chromogen (Peroxidase substrate kit, DAB sk-
4100, Vector Laboratories) and counterstaining was done with hematoxylin. 
Sections were dehydrated through 96% ethanol for 1min and absolute ethanol 
for 3min, and cleared in xylene for 5min. Slides were mounted with balsam and 
images were obtained by light microscopy using a Leica DM2000 microscope 
with a ×40 objective, a Leica DFC400 digital camera and Leica Application 
Suite software (Leica Microsystems, Wetzlar, Germany). At least 20 optical 
fields were examined and representative images were photographed. 
Statistical analysis
GraphPad Prism statistical program by GraphPad Software, Inc. (San Diego, 
CA, USA) was used. Results are expressed as the media ± S.E.M of the 
indicated number (n) of different individuals or experiments. Two-way ANOVA 
and Bonferroni post-test were used to assess age and genotype, sex and 
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genotype, or age and sex differences in GAL1 expression in normal and GH-
transgenic mice. Unpaired Student’s t-test was applied to compare control and 
transgenic mice only when old mice were analyzed. Paired Student’s t-test was 
used to compare GAL1 expression between tumors and non-tumoral adjacent 
tissue. Unpaired Student’s t-test was used to compare GAL1 protein levels 
between control and GH-treated Swiss-Webster mice for each sex. When GAL1 
protein/mRNA expression was compared between control and GH-treated cells, 
unpaired Student’s t-test, one-way or two-way ANOVA and Bonferroni post-test, 
were applied accordingly to the number of experimental conditions evaluated. 
When several groups were analyzed in parallel and/or a considerable 
dispersion of values was obtained for some groups, the concomitant loss of 
sensitivity prevented to find statistically significant differences by two-way 
ANOVA although these differences were evident. In these cases, unpaired 
Student’s t-test was used to compare two groups separately. All tests were two-
sided, and a P value < 0.05 was considered statistically significant.
Results 
GAL1 expression is up-regulated in the liver of GH-transgenic mice 
throughout life and is evident even in the absence of neoplastic pathology
To examine the possible role of GAL1 during GH-related liver tumor 
progression, we first examined GAL1 expression in liver extracts of three 
representative ages: a) two week-old, when animals of both genotypes exhibit 
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similar body size; b) four week-old, when transgenic mice start to display 
different body proportions than normal siblings; and c) nine week-old (young 
adults), showing clear enlargement of body size and exhibiting preneoplastic 
changes in the liver (30). Age-matched non-transgenic siblings were used as 
controls and both male and female mice were analyzed in parallel. 
We found elevated GAL1 protein levels in 2-week-old mice compared to 
older animals in both female and male transgenic mice (Fig. 1 A and B). A 
similar profile was observed for normal mice, despite only statistically significant 
for males. However, when non-transgenic males and females were analyzed 
independently, age-differences were statistically significant for both sexes and 
no gender-related differences were found (Supplementary Fig. 1 A). Gal1 
mRNA expression exhibited a different age-profile. In GH-transgenic mice, while 
similar levels between ages were obtained for females, lower mRNA levels 
were found in 4-week-old transgenic males in comparison to 2- and 9-week-old 
male mice (Fig. 1 C and D). In normal mice, Gal1 mRNA expression displayed a 
decrease with age, statistically significant when evaluated separately, and no 
differences between males and females were found, similar to what was 
observed for GAL1 protein levels (Supplementary Fig. 1 B). Different GAL1 
expression between genotypes was evident when age-matched control and 
GH-transgenic mice were compared. Both female and male GH-transgenic mice 
at 2 weeks of age showed higher GAL1 protein content in the liver than control 
mice, but this increase was statistically different only in females (Fig. 1 A and 
B). GAL1 protein levels in the liver of 4- and 9-week-old transgenic mice were 
also up-regulated with respect to age-matched control mice (Fig. 1 A and B). 
These differences were statistically significant when each age was analyzed 
Page 13 of 43 Accepted Manuscript published as EC-19-0292. Accepted for publication: 04-Jul-2019
Copyright © 2019 the authors Downloaded from Bioscientifica.com at 07/06/2019 01:09:41AM
via free access
14
separately by Student’s t-test (P<0.05). Gal1 mRNA expression was also higher 
in the liver of transgenic animals as compared with control mice at every age 
studied and for both sexes (Fig. 1 C and D). 
To further confirm GAL1 expression and assess its cellular localization, 
immunohistochemical studies were performed in liver sections from 9-week-old 
transgenic and control mice. Representative microphotographs are shown in 
Fig. 1 E for female mice; yet similar results were obtained for males 
(Supplementary Fig. 2 A). GAL1 staining was stronger in liver sections from 
transgenic mice, particularly at the cytoplasm of enlarged hepatocytes around 
the vasculature structures. Areas of dysplasia with large cellular and nuclear 
size and nuclear polymorphism of hepatocytes, predominantly in the 
centrolobullar areas within the liver of young adult transgenic mice were 
previously reported (17). Negative controls demonstrated the specificity of the 
reaction (Supplementary Fig. 2 B).
Thus, prolonged exposure to high levels of GH up-regulates GAL1 
expression in the liver of GH-transgenic mice at early ages, when animals 
display no or minimal histological alterations in this tissue, and also in young 
adults with preneoplastic liver pathology.
GAL1 up-regulation in the liver of GH-transgenic mice is sustained during 
aging and particularly enhanced in hepatic tumors
Up-regulation of GAL1 in human HCC correlates with tumor progression and 
aggressiveness (20, 22). GH-transgenic mice develop spontaneous 
hepatocellular tumors, including adenoma and carcinoma within one year of age 
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(11, 12). Therefore, we determined GAL1 expression in the liver of 10-13-
month-old GH-transgenic mice. These mice are regarded as old since GH 
overexpression is related to premature aging and a shorter mean life span than 
normal mice (13, 14). GAL1 protein and mRNA levels significantly increased in 
the liver of these animals as compared to age-matched control mice (Fig. 2 A 
and B). The protein levels of GAL1 in males and in females were analyzed 
separately. In females, GAL1 protein content was approximately 28-fold higher 
in GH-transgenic mice than in normal controls, while in males GH-transgenic 
animals displayed a 6.6-fold increase compared with controls (Fig. 2 A). In the 
case of Gal1 mRNA content, both sexes were analyzed in parallel. In control 
mice, Gal1 mRNA levels were lower in males than in females (statistically not 
significant by two-way ANOVA, significantly different by Student’s t-test, 
P<0.001). In contrast, in transgenic animals these levels were slightly higher in 
males than in females; however, the differences observed in Gal1 mRNA 
content between sexes did not achieve statistical significance. When we 
analyzed differences between genotypes, we observed that Gal1 mRNA levels 
were higher in old GH-transgenic mice than in their respective normal controls 
in both sexes. Gal1 mRNA content increased 4.5-fold in female GH-transgenic 
mice and 15-fold in males, compared to normal controls of the same sex (Fig. 2 
B).  
Remarkably, we found that liver tumors of old transgenic mice showed 
increased GAL1 protein expression compared to non-tumoral adjacent tissues, 
both in females and males (Fig. 2 C). Gal1 mRNA levels also increased in 
hepatic tumors, but this increase was statistically significant only in females 
(Fig. 2 D). In immunohistochemical assays, GAL1 staining in old transgenic 
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mice was observed in both tumoral and non-tumoral liver tissues, but the 
strongest intensity was particularly evident within tumors (Fig. 2 E, 
Supplementary Fig. 2 C). Similar to 9-week-old animals, GAL1 staining was 
detected mainly at the cytoplasm of enlarged hepatocytes around blood 
vessels.
Therefore, GAL1 up-regulation in the liver of GH-transgenic mice was 
preserved until advanced ages and was particularly high in hepatic tumors, 
suggesting the possible role of this lectin at different stages of 
hepatocarcinogenesis.
GAL1 is not up-regulated in other tissues of GH-transgenic mice
To study the influence of prolonged exposure to high GH levels in other tissues 
of transgenic mice, we assessed GAL1 expression in kidney, heart and skeletal 
muscle extracts from adult females. Immunoblotting experiments revealed that 
GAL1 up-regulation was not a general outcome of GH overexpression in every 
GH-target tissue, since GAL1 levels were not increased in kidney, heart or 
skeletal muscle of GH-transgenic mice (Fig. 3).
Continuous administration of GH increases GAL1 expression in mouse 
liver
To confirm our findings, we then investigated if GAL1 up-regulation was also 
induced upon continuous exposure to GH in another experimental model. GH 
was subcutaneously delivered to young adult Swiss-Webster mice by 
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continuous infusion with osmotic minipumps for 5 days. Notably, sustained 
administration of GH also increased liver GAL1 protein expression in males, but 
not in females (Fig. 4). The sexual dimorphism observed is in line with a 
previous report describing that continuous administration of the hormone for 5 
days caused a decrease on the expression of major urinary proteins (MUPs) in 
the liver in male mice, but it had no effect in female mice (27). Other authors 
also showed sexual differences in the liver expression of several genes and 
upon continuous administration of GH (32, 33, 34). Thus, GH may induce GAL1 
up-regulation in mouse liver not only when overexpressed as a transgene 
throughout life, but also when this hormone is continuously administered for a 
short period. 
GH induces GAL1 expression in human HCC cells
To investigate whether the up-regulation of GAL1 observed in mouse liver is a 
direct consequence of GH, we then evaluated its effect on GAL1 expression in 
human HepG2 and HuH-7 HCC cells. We previously demonstrated that the up-
regulation of GAL1 promotes HepG2 cell proliferation and epithelial-
mesenchymal transition in vitro, and tumor growth and metastasis in vivo (24, 
28, 29). We first evaluated GAL1 protein expression in HepG2 cells treated with 
GH for different times in parallel, and found that at 30min GH treatment was 
associated with higher mean levels of GAL1, which did not attain statistical 
significance since the number of experiments of these pilot experiments was 
low (n=4) (Supplementary Fig. 3 A). Moreover, GH appeared to exert a rapid 
and transient effect, since no apparent changes were observed upon hormone 
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treatment for 24h (Supplementary Fig. 3 B). As we observed similar effects on 
GAL1 protein levels using both supraphysiological GH concentrations of 0.5 and 
1µg/ml in HepG2 cells, we continued performing the experiments with the 
higher one, in order to mimic the increased levels of GH in transgenic animals 
(Supplementary Fig. 3 C). We therefore performed independent experiments to 
determine GAL1 protein content in cells incubated in the presence of GH for 
30min, both in HepG2 and in HuH-7 cells, and confirmed that this treatment 
significantly increased GAL1 protein content in both cell lines (Fig. 5 A). 
The effect of GH treatment on GAL1 mRNA levels was less clear, with a 
tendency towards an increase after 3h in both cell lines, and at 15min only in 
HepG2 cells (Fig. 5 B); however, these differences were not significantly 
different when analyzed by two-way ANOVA. 
Therefore, GH up-regulates GAL1 protein levels in vitro in human HCC 
cells. Although the precise mechanism is far from being elucidated, these 
results indicate that GH may act directly on hepatocytes to promote GAL1 
protein expression.
Discussion
Accumulating evidence suggests a remarkable contribution of GAL1 to HCC 
progression, aggressiveness and metastasis (20, 22). Because increased GH 
levels are associated with poor patient survival in human HCC (35), we 
investigated the involvement of GAL1 in GH-related liver tumor progression 
using transgenic mice overexpressing this hormone. Our findings demonstrate 
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that both GAL1 protein and mRNA expression were elevated in the liver of 2-
week-old control mice, suggesting up-regulation of this lectin early during the 
postnatal period. Subsequently, liver GAL1 expression declined considerably. 
These results are in line with previous findings showing GAL1 up-regulation 
during liver regeneration after partial hepatectomy (36), whereas low levels of 
this protein are found in human normal adult liver (18, 19). 
Remarkably, we found that prolonged exposure to GH in vivo up-
regulated GAL1 in the liver of transgenic animals and this effect was 
accentuated in tumors of older mice. Supporting these findings, GH induced 
hepatic GAL1 expression when this hormone was continuously administered for 
a short period. Interestingly, the results obtained with murine HCC models 
suggested that GAL1 may act as a protective anti-inflammatory agent at early 
stages of chronic liver pathology and as a pro-tumorigenic agent at late stages 
of the disease contributing to HCC growth and metastasis (37, 38).  Because of 
the broad immunosuppressive and pro-angiogenic activities of GAL1 within 
tumor microenvironments (20, 29, 39), its upregulation could, at least in part, 
mediate GH-driven hepatocarcinogenesis. Recently, it was demonstrated that 
mRNA and protein levels of galectin 3, another member of the galectin family, 
are increased in a murine ischemia-reperfusion model flap. Notably, GH 
administration ameliorated the inflammatory response, apoptosis and the 
pathological damage of the ischemia-reperfusion flap and also, partially reduced 
galectin 3 protein levels (40). These results suggest that within an inflammatory 
context, not only in the liver, GH may modulate the expression of galectins.
We have previously demonstrated that several signaling pathways 
involved in cell growth, proliferation and survival are deregulated in 
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preneoplastic livers of GH-transgenic mice and these molecular alterations 
resemble those found in many human tumors (17, 41). Interestingly, we also 
reported that many signaling mediators and effectors of these oncogenic 
pathways were also induced by GAL1 overexpression in human HCC cells, and 
that this lectin contributes to tumor growth and dissemination (24, 28, 29). Here, 
we report that GH rapidly induces GAL1 protein expression in human HCC 
cells, suggesting that this lectin could be implicated in hormone-driven liver 
carcinogenesis. 
Increased mRNA and protein levels of both GAL1 and GH were 
observed in human HCC compared with non-tumoral liver tissue (18, 19, 35). 
Furthermore, GAL1 and GH overexpression or their elevated serum levels 
correlated with advanced HCC, metastasis and worse clinical outcome (21, 23, 
25, 35). Although the precise mechanisms underlying GH-induced GAL1 
expression are yet to be elucidated, our findings suggest a potential role for this 
lectin as a mediator of GH-driven tumorigenesis and potential biomarker of liver 
cancer risk that should be further explored. 
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GAL1 expression is increased in the liver of young GH-transgenic mice. Liver 
extracts of control (C) and GH-transgenic (T) mice of three representative ages: 
2 week-old (2w), 4 week-old (4w) and 9 week-old (9w, considered young adults 
and used as reference) were evaluated for GAL1 protein expression by Western 
blotting and densitometric analysis in females and males (panels A and B, 
respectively). Protein loading control was performed by Coomassie blue 
staining (CBS) of PVDF membranes. Liver Gal1 mRNA levels relative to 
cyclophilin A were determined by RT-qPCR analysis in females and males 
(panels C and D, respectively). Data are the mean ± SEM of the indicated 
number of samples per group (n), each one representing a different animal. 
Different letters denote significant differences by age (P<0.05), small letters 
correspond to normal mice and capital letters to transgenic animals; asterisks 
indicate differences between genotypes analyzed by two-way ANOVA followed 
by Bonferroni post-test (*P<0.05, **P<0.01, ***P<0.001). GAL1 expression and 
cellular localization were evaluated by immunohistochemistry in the liver of 9-
week-old animals (panel E). Three independent experiments were performed 
with reproducible results and representative microphotographs are shown for 
liver sections of female mice. Similar results were obtained for males 
(Supplementary Fig. 2 A). Negative controls were performed in parallel in all 
sections by incubation without primary antibody (Supplementary Fig. 2 B). 
Figure 2
Page 30 of 43Accepted Manuscript published as EC-19-0292. Accepted for publication: 04-Jul-2019
Copyright © 2019 the authors Downloaded from Bioscientifica.com at 07/06/2019 01:09:41AM
via free access
31
GAL1 is up-regulated in the liver and in hepatic tumors of old GH-transgenic 
mice. GAL1 expression was assessed in the liver of control (C) and GH-
transgenic (T) mice of 10-13 months old by Western blotting and densitometric 
analysis (panel A) and RT-qPCR assay (panel B). Protein loading control was 
performed by Coomassie blue staining (CBS) of PVDF membranes. Tumoral 
(Tu) and non-tumoral (NTu) zones for the same GH-transgenic animal were 
processed in parallel and GAL1 protein content (panel C) and mRNA levels 
relative to cyclophilin A (panel D) were determined. Data are the mean ± SEM 
of the indicated number of samples per group (n), each one representing a 
different animal. The same letter denotes no significant difference between 
sexes, small letters correspond to normal mice and capital letters to transgenic 
animals; the symbol # indicates differences between genotypes analyzed by 
two-way ANOVA followed by Bonferroni post-test (###P<0.001). Asterisks 
indicate differences analyzed by Student’s t-test (*P<0.05, ***P<0.001). Liver 
sections from control and transgenic mice were processed for 
immunohistochemistry to analyze GAL1 expression and localization. Tumoral 
(Tu) and non-tumoral (NTu) tissue were processed in parallel (panel E). Three 
independent experiments were performed with reproducible results and 
representative microphotographs are shown for liver sections of female mice. 
Similar results were obtained for males (data not shown). Negative controls 
were performed by omitting primary antibody (Supplementary Fig. 2 C).
Figure 3
Prolonged exposure to GH does not increase GAL1 expression in the kidney, 
muscle or heart of GH-transgenic mice. Kidney (panel A), heart (panel B) and 
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skeletal muscle (panel C) extracts from adult control (C) and GH-transgenic (T) 
females were evaluated for GAL1 expression by Western blotting and analyzed 
by densitometry. Protein loading control was performed by Coomassie blue 
staining (CBS) of PVDF membranes. Data are the mean ± SEM of the indicated 
number of samples per group (n), each one representing a different animal. No 
significant differences were obtained when analyzed by Student’s t test.
Figure 4
GAL1 expression is induced in the liver of GH-treated Swiss-Webster mice. 
Liver extracts of female and male mice treated for 5 days with GH (1mg/kg of 
body weight per day) by continuous infusion with an osmotic minipump (GH) or 
their respective controls (C) were evaluated for GAL1 protein expression by 
Western blotting and analyzed by densitometry. Protein loading control was 
performed by β-actin immunoblotting. Data are the mean ± SEM of the indicated 
number of samples per group (n), each one representing a different animal. 




GAL1 expression is induced by GH in human HCC cells in vitro. Western 
blotting and densitometric analysis showing GAL1 protein expression in HepG2 
and HuH-7 HCC cells treated with serum-free media containing GH (1µg/ml) or 
vehicle (C, control cells used as reference) for 30min (panel A). Protein loading 
control was performed by β-actin immunoblotting. GAL1 mRNA levels relative to 
RPL13A were determined by RT-qPCR analysis in cells cultured in the 
presence of GH (1µg/ml) (HepG2-GH and HuH-7-GH) and in control cells 
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(HepG2-C and HuH-7-C) for 15min or 3h (panel B). Results are expressed as 
fold change versus values measured for untreated cells at the beginning of the 
experiment (t0). Data are the mean ± SEM of the indicated number of different 
experiments (n). Asterisks indicate differences induced by GH-stimulus 
analyzed by Student’s t-test (*P<0.05) (panel A). No significant differences were 
found by two-way ANOVA followed by Bonferroni post-test analysis (panel B). 
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Supplementary Figure 1
GAL1 expression in the liver of control wild type mice at different ages. Liver 
extracts of control mice of three representative ages: 2 weeks-old (2w), 4 weeks-
old (4w) and 9 weeks-old (9w, considered young adults and used as reference) 
were evaluated for GAL1 protein content by Western blotting and densitometric 
analysis (panel A). Liver Gal1 mRNA levels were determined by RT-qPCR analysis 
(panel B). Data are the mean ± SEM of the indicated number of samples per group 
(n), each one representing a different animal. Different letters denote significant 
differences by age; small letters correspond to female mice and capital letters to 
male animals, analyzed by two-way ANOVA followed by Bonferroni post-test 
(P<0.05).
Supplementary Figure 2
GAL1 expression and cellular localization were evaluated by 
immunohistochemistry in the liver of 9-week-old GH transgenic and control animals 
(panel A). Three independent experiments were performed with reproducible 
results and representative microphotographs are shown for liver sections of male 
mice. Immunohistochemical assay negative controls were performed by omitting 
the primary antibody. Representative microphotographs are shown for liver 
sections of 9-week-old (panel B) and 13-month-old (panel C) control and 
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animal were processed in parallel.
Supplementary Figure 3
GAL1 protein expression in human HCC cells after treatment with GH. Western 
blotting and densitometric analysis showing GAL1 protein content in HepG2 and 
HuH-7 HCC cells treated with serum-free media containing GH (1µg/ml) or vehicle 
(C, control cells used as reference) for 15min, 30min, 1h, 3h (panel A) and 24h 
(panel B). HepG2 cells were incubated for 30min with serum-free media containing 
GH at 0.5µg/ml or 1µg/ml (panel C). Protein loading control was performed by β-
actin immunoblotting. Results are expressed as fold change versus values 
measured for untreated cells at 30min (A, C) or 24h (B). Data are the mean ± SEM 
of the indicated number of different experiments (n). No significant differences 
were obtained when two-way ANOVA (panel A) or one-way ANOVA (panel C) 
followed by Bonferroni post-test, or Student’s t test (panel B) were applied.
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Figure 1. GAL1 expression is increased in the liver of young GH-transgenic mice. 
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Figure 2. GAL1 is up-regulated in the liver and in hepatic tumors of old GH-transgenic mice. 
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Figure 3. Prolonged exposure to GH does not increase GAL1 expression in the kidney, muscle or heart of 
GH-transgenic mice. 
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Figure 4. GAL1 expression is induced in the liver of GH-treated Swiss-Webster mice. 
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Figure 5. GAL1 expression is induced by GH in human HCC cells in vitro. 
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Supplementary Fig. 1. GAL1 expression in the liver of control wild type mice at different ages. 
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Supplementary Fig. 2. GAL1 expression and cellular localization by immunohistochemistry. 
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Supplementary Fig. 3. GAL1 protein expression in human HCC cells after treatment with GH. 
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